Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial
Journal of Urology | August 26, 2021 | Volume: 207 | Issue: 1 | Pages: 61-69
10.1097/ju.0000000000002186
| PMID 34433303